Related Experiment Video
Updated: Mar 22, 2026
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Opportunities and challenges for TCR mimic antibodies in cancer therapy
Aaron Y Chang1,2, Ron S Gejman1,2, Elliott J Brea1,2
1a Molecular Pharmacology Program, Immunology Program, Memorial Sloan Kettering Cancer Center , New York , NY , USA.
Introduction:
Monoclonal antibodies (mAbs) are potent cancer therapeutic agents, but exclusively recognize cell-surface targets whereas most cancer-associated proteins are found intracellularly. Hence, potential cancer therapy targets such as over expressed self-proteins, activated oncogenes, mutated tumor suppressors, and translocated gene products are not accessible to traditional mAb therapy. An emerging approach to target these epitopes is the use of TCR mimic mAbs (TCRm) that recognize epitopes similar to those of T cell receptors (TCR).
Areas Covered:
TCRm antigens are composed of a linear peptide sequence derived from degraded proteins and presented in the context of cell-surface MHC molecules. We discuss how the nature of the TCRm epitopes provides both advantages (absolute tumor specificity and access to a new universe of important targets) and disadvantages (low density, MHC restriction, MHC down-regulation, and cross-reactive linear epitopes) to conventional mAb therapy. We will also discuss potential solutions to these obstacles.
Expert Opinion:
TCRm combine the specificity of TCR recognition with the potency, pharmacologic properties, and versatility of mAbs. The structure and presentation of a TCRm epitope has important consequences related to the choice of targets, mAb design, available peptides and MHC subtype restrictions, possible cross-reactivity, and therapeutic activity.
Insights
TCR mimic monoclonal antibodies (mAbs) offer a novel approach to target intracellular cancer proteins, overcoming limitations of traditional mAbs. These TCR mimic mAbs provide tumor specificity but face challenges like low epitope density and MHC restriction.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Monoclonal antibodies (mAbs) are effective cancer therapeutics but are limited to cell-surface targets.
- Most cancer-associated proteins are intracellular, rendering them inaccessible to traditional mAb therapy.
- TCR mimic mAbs (TCRm) emerge as a strategy to target intracellular epitopes via T cell receptor (TCR)-like recognition.
Purpose of the Study:
- To explore the potential of TCR mimic mAbs (TCRm) for targeting intracellular cancer proteins.
- To discuss the advantages and disadvantages of TCRm epitopes in cancer therapy.
- To review potential solutions for overcoming obstacles associated with TCRm therapy.
Main Methods:
- Review of TCR mimic mAb (TCRm) antigen structure and presentation.
- Analysis of TCRm epitope characteristics, including specificity and density.
- Discussion of MHC restriction and potential cross-reactivity issues.
Main Results:
- TCRm antigens are linear peptides presented by MHC molecules, enabling access to intracellular targets.
- TCRm offer absolute tumor specificity and a new universe of therapeutic targets.
- Challenges include low epitope density, MHC restriction, MHC down-regulation, and cross-reactivity.
Conclusions:
- TCRm mAbs combine TCR specificity with mAb versatility for cancer therapy.
- Understanding TCRm epitope structure and presentation is crucial for mAb design and therapeutic efficacy.
- Addressing challenges like MHC restriction and cross-reactivity is key to successful TCRm-based cancer treatment.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:38Mitogens and the Cell Cycle